• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

News of the day

Industry news search

Recent news

To keep up to date with news from this category use our

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL
Massachusetts - 21 Oct 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration...

Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc
Mechelen, Belgium 14 October 2009 - Galapagos NV (Euronext: GLPG) announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the...

Data on VIVUS' Qnexa To Be Featured at The Obesity Society Annual Meeting
MOUNTAIN VIEW, Calif., Oct 05, 2009 -- VIVUS,Inc. (Nasdaq: VVUS) today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS)...

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin
Ingelheim/Germany, 28 September 2009 - Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials....

Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
SAN DIEGO, Sept 18, 2009 -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity...

ConjuChem Announces Fiscal 2009 Third Quarter Financial Results
MONTREAL, Canada, September 14, 2009 - ConjuChem Biotechnologies (TSX:CJB) today announced financial results for the third quarter of fiscal 2009, ended July 31, 2009. "During our fiscal third quarter, we had the...

Aegis Therapeutics and Albany Medical College Expand Collaboration for Novel Oral Anti-Obesity Drug
SAN DIEGO, CA August 26, 2009 - Aegis Therapeutics and Albany Medical College announced today that they have expanded their existing research relationship, entering into a joint commercialization agreement to promote...